SLC6A8 is a Potential Biomarker for Poor Prognosis in Lung Adenocarcinoma

作者：Yongfei Fan, Yong Zhou, Ming Lou, Zhaojia Gao, Xinwei Li, Kai Yuan · 发表于：Frontiers in Genetics · 年份：2022 · DOI：10.3389/fgene.2022.845373 · 被引用次数：10 · 研究领域：RNA modifications and cancer、Cancer-related molecular mechanisms research、Ferroptosis and cancer prognosis

Background: Recent studies have demonstrated that creatine can promote tumor metastasis and has implications for immune cell function. SLC6A8 encodes a membrane protein that can transport creatine inside and outside the cell. However, there are currently no studies of SLC6A8 in lung adenocarcinoma (LUAD). Methods: In this study, the expression of SLC6A8 in LUAD was analyzed using the Oncomine database, the Cancer Genome Atlas (TCGA) database, and immunohistochemical staining analysis. Survival analysis of patients with LUAD was performed using the cBioPortal and the Kaplan-Meier Plotter websites and clinical follow-up data. An analysis of the association between SLC6A8 and the tumor immune microenvironment (TIME) of LUAD was performed through the TISIDB database and estimation of stromal and immune cells in malignant tumor tissues using expression data (ESTIMATE) algorithm. Then, based on the curated list of SLC6A8 -related immunomodulators, three genes ( NT5E, CD40LG, CD80 ) were selected to construct SLC6A8 -related immune signatures to further evaluate the immune aspect of LUAD prognosis. Results: Our studies indicated that SLC6A8 was overexpressed in LUAD, and the high expression of SLC6A8 was associated with poor survival. Genetic alteration of SLC6A8 was also associated with a poorer prognosis. Furthermore, multivariate Cox analysis indicated that SLC6A8 could be used as an independent risk prognostic factor. Then, immune infiltration analysis indicated that SLC6A8 was ...